Alnylam Pharmaceuticals (NASDAQ:ALNY) Stock Gets Price Target Reduction from Morgan Stanley

Alnylam Pharmaceuticals (NASDAQ:ALNY) had its price target dropped by investment analysts at Morgan Stanley from $300.00 to $240.00 in a research note issued on Friday, Benzinga reports. The brokerage currently has an “equal weight” rating on the biopharmaceutical company’s stock. Morgan Stanley‘s price target indicates a potential upside of 42.90% from the company’s current price.

A number of other research firms also recently weighed in on ALNY. Chardan Capital reissued a “buy” rating and set a $425.00 target price on shares of Alnylam Pharmaceuticals in a research report on Friday, July 31st. Wall Street Zen lowered Alnylam Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a report on Sunday, August 2nd. Wells Fargo & Company dropped their target price on Alnylam Pharmaceuticals from $253.00 to $220.00 and set an “equal weight” rating on the stock in a report on Friday. Truist Financial reduced their price target on Alnylam Pharmaceuticals from $410.00 to $315.00 and set a “buy” rating for the company in a research note on Tuesday, August 4th. Finally, Raymond James Financial lowered shares of Alnylam Pharmaceuticals from a “strong-buy” rating to an “outperform” rating and decreased their target price for the company from $420.00 to $315.00 in a report on Friday. One analyst has rated the stock with a Strong Buy rating, seventeen have issued a Buy rating and nine have assigned a Hold rating to the stock. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average target price of $325.50.

Alnylam Pharmaceuticals Price Performance

Shares of NASDAQ ALNY traded down $6.05 during midday trading on Friday, reaching $167.95. The company’s stock had a trading volume of 3,274,349 shares, compared to its average volume of 1,500,848. Alnylam Pharmaceuticals has a one year low of $167.16 and a one year high of $479.79. The company has a 50 day moving average price of $237.78 and a 200 day moving average price of $287.22. The company has a market cap of $22.47 billion, a price-to-earnings ratio of 31.22 and a beta of 0.28. The company has a current ratio of 3.05, a quick ratio of 2.99 and a debt-to-equity ratio of 0.75.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last issued its quarterly earnings results on Thursday, October 29th. The biopharmaceutical company reported $16.26 EPS for the quarter, beating the consensus estimate of $1.66 by $14.60. Alnylam Pharmaceuticals had a net margin of 15.26% and a return on equity of 84.93%. The business had revenue of $1.46 billion during the quarter, compared to the consensus estimate of $1.43 billion. During the same quarter in the prior year, the firm earned $2.90 EPS. The firm’s quarterly revenue was up 16.7% on a year-over-year basis. On average, equities research analysts expect that Alnylam Pharmaceuticals will post 6.43 EPS for the current year.

Insider Buying and Selling

In other Alnylam Pharmaceuticals news, EVP Bryan Supran sold 1,758 shares of the firm’s stock in a transaction on Friday, October 2nd. The stock was sold at an average price of $226.88, for a total value of $398,855.04. Following the completion of the sale, the executive vice president directly owned 12,807 shares of the company’s stock, valued at $2,905,652.16. This trade represents a 12.07% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders own 0.86% of the company’s stock.

Institutional Inflows and Outflows

A number of hedge funds have recently bought and sold shares of ALNY. Toth Financial Advisory Corp purchased a new stake in Alnylam Pharmaceuticals during the 3rd quarter worth about $25,000. Burkett Financial Services LLC bought a new position in shares of Alnylam Pharmaceuticals in the third quarter worth $37,000. CoreCap Advisors LLC raised its position in shares of Alnylam Pharmaceuticals by 744.4% in the third quarter. CoreCap Advisors LLC now owns 152 shares of the biopharmaceutical company’s stock worth $38,000 after buying an additional 134 shares in the last quarter. Keating Financial Advisory Services Inc. purchased a new stake in shares of Alnylam Pharmaceuticals in the second quarter worth $42,000. Finally, Root Financial Partners LLC bought a new stake in Alnylam Pharmaceuticals during the third quarter valued at $48,000. 92.97% of the stock is currently owned by hedge funds and other institutional investors.

More Alnylam Pharmaceuticals News

Here are the key news stories impacting Alnylam Pharmaceuticals this week:

• Positive Sentiment: Q3 results exceeded expectations. Alnylam reported $16.26 in adjusted earnings per share versus the $1.66 consensus estimate, while revenue rose 16.7% year over year to $1.46 billion, ahead of estimates. The company maintained its fiscal 2026 net product-sales outlook. Alnylam Q3 earnings and revenue results
• Positive Sentiment: Long-term pipeline prospects remain supportive. Alnylam expects $4.2 billion-$4.5 billion in 2026 TTR sales and expanded the TRITON-CM nucresiran heart-disease study to approximately 2,250 patients while maintaining an expected launch timeline around 2030. Alnylam TTR sales and TRITON-CM update
• Neutral Sentiment: Analysts remain divided. Wells Fargo lowered its target to $220 and kept an “equal weight” rating; RBC cut its target to $280 but retained “outperform”; and Needham reduced its target to $243 while maintaining “buy.” These targets still imply substantial potential upside from recent levels.
• Negative Sentiment: Demand growth is the immediate concern. Slower U.S. Amvuttra patient starts and moderating Amvuttra and Onpattro sales growth raised questions about the pace of commercial expansion despite the quarterly beat. Alnylam demand growth concerns
• Negative Sentiment: Broker sentiment weakened. Bernstein downgraded Alnylam to “market perform” with a $199 target, while Stifel cut its rating to “hold” and set a $225 target. The reductions reflect greater caution around near-term growth and valuation.
• Negative Sentiment: Additional risk overhangs remain. An investor law firm announced an investigation related to a prior company disclosure, potentially adding to market uncertainty, although no wrongdoing has been established. Alnylam investor investigation

Alnylam Pharmaceuticals Company Profile

Alnylam Pharmaceuticals, Inc is a biopharmaceutical company focused on developing and commercializing medicines based on RNA interference (RNAi). The company’s therapies are designed to silence specific genes involved in disease, with the goal of addressing the underlying causes of genetic and other serious conditions.

Alnylam’s marketed products include ONPATTRO (patisiran) and AMVUTTRA (vutrisiran) for hereditary transthyretin-mediated amyloidosis, GIVLAARI (givosiran) for acute hepatic porphyria, and OXLUMO (lumasiran) for primary hyperoxaluria type 1.